Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court

The appellate judges decline to rule on the validity of FDA’s patent-by-patent approach to awarding generic marketing exclusivity in either case. Apotex’ challenge to Purepac’s gabapentin exclusivity is barred by earlier litigation, court says; FDA’s appeal stemming from paroxetine exclusivity ruling is dismissed as moot.